|41.05||+2.94||+7.71%||Vol 2.29M||1Y Perf -68.90%|
|Jun 24th, 2022 16:00 DELAYED|
|- -||-2.05 -4.99%|
|Target Price||38.25||Analyst Rating||Moderate Buy 2.50|
|Potential %||-6.82||Finscreener Ranking||★★★ 49.86|
|Insiders Trans % 3/6/12 mo.||-83/-94/-99||Value Ranking||★★★★ 55.66|
|Insiders Value % 3/6/12 mo.||-43/-81/-99||Growth Ranking||★★★ 52.56|
|Insiders Shares Cnt. % 3/6/12 mo.||-31/-67/-97||Income Ranking||— -|
|Price Range Ratio 52W %||13.91||Earnings Rating||Strong Buy|
|Market Cap||2.31B||Earnings Date||5th Aug 2022|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th Aug 2022|
|Estimated EPS Next Report||-1.30|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.68M|
|Avg. Monthly Volume||1.30M|
|Avg. Quarterly Volume||1.12M|
Twist Bioscience Corporation (NASDAQ: TWST) stock closed at 41.05 per share at the end of the most recent trading day (a 7.71% change compared to the prior day closing price) with a volume of 2.29M shares and market capitalization of 2.31B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 525 people. Twist Bioscience Corporation CEO is Emily M. Leproust.
The one-year performance of Twist Bioscience Corporation stock is -68.9%, while year-to-date (YTD) performance is -46.96%. TWST stock has a five-year performance of %. Its 52-week range is between 25.07 and 139.99, which gives TWST stock a 52-week price range ratio of 13.91%
Twist Bioscience Corporation currently has a PE ratio of -8.40, a price-to-book (PB) ratio of 2.03, a price-to-sale (PS) ratio of 10.75, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -22.58%, a ROC of -23.64% and a ROE of -25.98%. The company’s profit margin is -%, its EBITDA margin is -115.00%, and its revenue ttm is $163.11 Million , which makes it $2.90 revenue per share.
Of the last four earnings reports from Twist Bioscience Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.30 for the next earnings report. Twist Bioscience Corporation’s next earnings report date is 05th Aug 2022.
The consensus rating of Wall Street analysts for Twist Bioscience Corporation is Moderate Buy (2.5), with a target price of $38.25, which is -6.82% compared to the current price. The earnings rating for Twist Bioscience Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Twist Bioscience Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Twist Bioscience Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 21.09, ATR14 : 3.05, CCI20 : 211.20, Chaikin Money Flow : 0.09, MACD : 0.46, Money Flow Index : 68.36, ROC : 33.32, RSI : 67.80, STOCH (14,3) : 98.46, STOCH RSI : 1.00, UO : 69.31, Williams %R : -1.54), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Twist Bioscience Corporation in the last 12-months were: Emily M. Leproust (Option Excercise at a value of $939 901), Emily M. Leproust (Sold 170 438 shares of value $19 379 839 ), James M. Thorburn (Option Excercise at a value of $787 638), James M. Thorburn (Sold 48 122 shares of value $3 634 192 ), Jan Johannessen (Option Excercise at a value of $210 000), Jan Johannessen (Sold 15 253 shares of value $1 372 296 ), Keith L. Crandell (Sold 90 000 shares of value $9 630 753 ), Nicolas M. Barthelemy (Buy at a value of $250 096), Patrick Finn (Option Excercise at a value of $471 190), Patrick Finn (Sold 27 281 shares of value $2 682 882 ), Patrick Weiss (Option Excercise at a value of $514 148), Patrick Weiss (Sold 29 141 shares of value $2 952 631 ), Robert B. Chess (Sold 16 253 shares of value $1 960 606 ), William Banyai (Option Excercise at a value of $200 246), William Banyai (Sold 128 755 shares of value $13 379 043 )
Mon, 09 May 2022 01:21 GMT Twist Bioscience (TWST) Gets a Buy Rating from Barclays- TipRanks. All rights reserved.
Sun, 08 May 2022 15:21 GMT Twist Bioscience (TWST) Gets a Hold Rating from SVB Securities- TipRanks. All rights reserved.
Sat, 12 Feb 2022 09:13 GMT Twist Bioscience (TWST) Gets a Sell Rating from J.P. Morgan- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.